Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding

Nicolas Gendron; Anne Laure Feral-Pierssens; Igor Jurcisin; Emmanuelle de Raucourt; Valerie Bouton; Anne Marie Fischer; Camille Lorenceau-Savale; Agnès Lillo-Le Louët; David M Smadja

doi:10.1002/ccr3.839

Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding

Clin Case Rep. 2017 Feb 10;5(3):346-350. doi: 10.1002/ccr3.839. eCollection 2017 Mar.

Authors

Nicolas Gendron¹, Anne Laure Feral-Pierssens², Igor Jurcisin³, Emmanuelle de Raucourt⁴, Valerie Bouton⁵, Anne Marie Fischer⁶, Camille Lorenceau-Savale⁷, Agnès Lillo-Le Louët⁸, David M Smadja¹

Affiliations

¹ Hematology Department AP-HP European Hospital Georges Pompidou Paris France; Sorbonne Paris Cite Université Paris Descartes Paris France; Inserm UMR-S1140 Paris France.
² Emergency Department AP-HP European Hospital Georges Pompidou Paris France.
³ Intensive Care Unit AP-HP Beaujon Hospital Paris France.
⁴ Hematology Department AP-HP Beaujon Hospital Paris France.
⁵ Pharmacy Department AP-HP Beaujon Hospital Paris France.
⁶ Hematology Department AP-HP European Hospital Georges Pompidou Paris France; Sorbonne Paris Cite Université Paris Descartes Paris France; Inserm UMR-S970 PARCC Paris France.
⁷ Department of Gastroenterology and Endoscopy AP-HP European Hospital Georges Pompidou Paris France.
⁸ Regional Center of Pharmacovigilance AP-HP European Hospital Georges Pompidou Paris France.

Abstract

Bleeding is a rare complication of direct oral anticoagulant potentially associated with high mortality rates. Biological monitoring is necessary for more than 24 h after idarucizumab antidote therapy in case of bleeding with dabigatran therapy.

Keywords: Anticoagulant; antidote; bleeding; dabigatran; idarucizumab; non‐VKA oral anticoagulants.

Publication types

Case Reports